Merging allosteric and active site binding motifs : de novo generation of target selectivity and potency via natural-product-derived fragments by Lanz, Jan & Riedl, Rainer
Merging Allosteric and Active Site Binding Motifs: De
novo Generation of Target Selectivity and Potency via
Natural-Product-Derived Fragments
Jan Lanz and Rainer Riedl*[a]
The de novo design of molecules from scratch with tailored
biological activity is still the major intellectual challenge in
chemical biology and drug discovery. Herein we validate natu-
ral-product-derived fragments (NPDFs) as excellent molecular
seeds for the targeted de novo discovery of lead structures for
the modulation of therapeutically relevant proteins. The appli-
cation of this de novo approach delivered, in synergy with the
combination of allosteric and active site binding motifs, highly
selective and ligand-efficient non-zinc-binding (3 : 4-{[5-(2-{[(3-
methoxyphenyl)methyl]carbamoyl}eth-1-yn-1-yl)-2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-1-yl]methyl}benzoic acid) as well as
zinc-binding (4 : 4-({5-[2-({[3-(3-carboxypropoxy)phenyl]methyl}-
carbamoyl)eth-1-yn-1-yl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-
1-yl}methyl)benzoic acid) uracil-based MMP-13 inhibitors pre-
senting IC50 values of 11 nm (3 : LE=0.35) and 6 nm (4 : LE=
0.31).
Despite the fact that a lot of progress has been made in struc-
ture-based drug design, there is still no general approach avail-
able for the de novo design of novel drugs. This problem has
been addressed by computational tools and by experimental
approaches, but it still remains the major challenge for chem-
ists in the search for innovative molecules to modulate biologi-
cal systems.[1]
Natural products can be considered as biologically validated
by evolution and should therefore be ideal starting points for
the discovery of bioactive molecules. They have facilitated
drug discovery in the past, but due to their chemical complexi-
ty their impact on drug discovery relative to synthetic small
molecules has decreased over time.[2] Recently, natural prod-
ucts have again drawn increasing attention in drug discovery
as a source of molecules that cover a complementary chemical
space relative to purely synthetic molecules.[3]
Fragment-based drug discovery has evolved as a new para-
digm in the search for small-molecule modulators of therapeu-
tic targets, as it allows the development of ligand-efficient
drug molecules by starting with small fragments rather than
with complex molecules such as natural products.[4] Very re-
cently, the chemical space targeted by fragments has been ex-
tended by the deconstruction of complex natural products in
order to provide biocompatible alternatives to synthetic frag-
ments.[5] However, the benefit of natural-product-derived frag-
ments (NPDFs) for the design of high-affinity ligands with se-
lectivity profiles suitable for clinical drug candidates has yet to
be proven.
In this study, we set out to establish NPDFs as powerful
seeds for the de novo creation of organic molecules with tail-
ored biological activity using matrix metalloproteinase 13
(MMP-13) as an exemplary target. We proved this paradigm by
the de novo design, synthesis, and biological evaluation of
potent, selective, and ligand-efficient MMP-13 inhibitors based
on uracil as the fragment seed (Figure 1).
MMP-13 is a highly relevant and validated target for a multi-
tude of severe diseases such as cancer,[9] osteoarthritis,[10] rheu-
matoid arthritis,[11] cardiovascular[12] and neurodegenerative dis-
eases.[13] MMP-13 is a member of the zinc-dependent endopep-
tidase family. It is the dominant MMP involved in type II colla-
gen cleavage in the degradation process of extracellular matrix
during growth and tissue remodeling.[14] All clinical candidates
containing strong zinc-binding groups have failed in clinical
Figure 1. Probing the MMP-13 S1’-binding site by uracil : Uracil addresses
the Met232 backbone NH/CO and the side chain amino functionality of
Lys228; molecular models generated with MOE;[6] images generated with
CHIMERA;[7] (MMP-13 PDB code: 2OW9);[8] C (protein): gray; C (inhibitor scaf-
fold): green; N: blue; O: red.
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trials.[15] Unsatisfying bioavailability and severe side effects due
to a lack of selectivity and the metabolic liability of zinc-bind-
ing functionalities such as hydroxamic acids has hampered
their development. Hence, the discovery of efficacious MMP in-
hibitors without strong zinc-binding functional moieties is
a very active field of research toward the generation of clinical
treatments for those serious conditions.[16]
Peptide bonds of the protein backbone represent the ubiq-
uitous binding motif for small molecules to modulate a biologi-
cal target. We used this omnipresent H-bonding motif as the
starting point for our de novo design concept based on
NPDFs. This combines 1) targeting an omnipresent binding
motif and 2) the use of biologically validated NPDFs as seeds
for de novo drug-design processes. This represents a general
de novo design approach by using biocompatible fragments,
thus preventing the use of synthetic fragments with debatable
biological properties.
First, we selected a NPDF that, based on its molecular archi-
tecture, is able to probe the binding site of a biological target
for possible H-bond interactions with the protein’s peptide
bonds. We chose uracil as NPDF because: 1) this fragment is
present in a multitude of very prominent natural products,
such as ribonucleic acid (RNA), 2) it offers several synthetic
anchor points for the development of a lead structure by or-
ganic synthesis, and 3) uracil interacts strongly with biomole-
cules such as adenine in RNA via H-bonds due to its cis amide
bonds. Starting with the bare protein of an MMP-13 X-ray crys-
tal structure (PDB code: 2OW9),[8] we probed the selectivity-en-
abling, non-zinc-binding S1’-binding site of the protein in silico
with uracil for preferred H-bonding interactions, and found
a remarkable conserved binding motif of the uracil molecule
within this allosteric binding site (Figure 1 and Figure S1, Sup-
porting Information (SI)).
Uracil interacts via its cis amide bonds with the backbone
NH and CO groups of Met232 in the top-ranked docking
poses. This binding motif has not been observed in any co-
crystal structure of MMP-13 with an inhibitor so far, and there-
fore offered a unique starting point for the de novo design of
novel non-zinc-binding MMP-13 inhibitors. In addition, uracil
addresses the side chain amino group of Lys228.
We exploited this distinctive binding motif to elongate the
uracil fragment by adding target-oriented functional fragments
to strengthen the affinity of the developing inhibitor scaffold:
1) N1-alkylation of the uracil fragment by a benzylic fragment
in order to interact with the aromatic side chains of Tyr225
and Phe231 via CH–p interactions, 2) elongation at uracil C5
by a linear propiolic acid fragment to interact with the back-
bone NH of Thr224 within the linear S1’-binding site, and
3) addition of a benzylic fragment to the propiolic acid termi-
nus to interact with His201 via p–p interaction (Figure 2 and SI
Figure S2; further design details are given in the Supporting In-
formation).
Subsequent synthesis of the inhibitor scaffold 2 was effi-
ciently carried out by starting with 5-iodouracil (1) using palla-
dium-catalyzed cross-coupling chemistry as the central CC
bond formation strategy, which is well suited for introducing
various substitution patterns (Scheme 1 and SI Scheme S1).[17]
The biological evaluation of scaffold 2 revealed a very prom-
ising initial affinity against MMP-13 and a superb selectivity
profile against a variety of other members of the MMP family,
as intended by our de novo design (Table 1).
We calculated the Tanimoto coefficients (JChem for Excel,
FP2, ChemAxon)[18] for scaffold 2 in comparison with all cur-
rently known MMP-13 inhibitors available through the ChEMBL
data base (www.ebi.ac.uk/chembl/, ChEMBL-ID: CHEMBL280,
2580 compounds) in order to evaluate the fingerprint-based
novelty of the uracil scaffold 2. The highest Tanimoto similarity
index was 0.43. This clearly indicates that based on the NPDF
uracil as molecular seed and our structure-based de novo
design approach we furnished a novel chemotype for MMP-13
inhibitors.[19]
Figure 2. Top-ranked docking pose of the de novo uracil-based MMP-13 in-
hibitor scaffold 2 within the allosteric binding site.
Scheme 1. Transformation of 5-iodouracil 1 into protease inhibitors 2–4 (full
synthetic details are given in the Supporting Information).
Table 1. Biological MMP inhibitory potency and selectivity profile.
Inhibitor MMP-13[a] MMP-1, -2, -3, -7, -8, -9, -12, -14[b]
2 5.13 mm
[pIC50=5.290.17]
<50% inhibition at 20 mm
3 10.90 nm
[pIC50=7.960.05]
<50% inhibition at 20 mm
4 5.78 nm
[pIC50=8.240.15]
<50% inhibition at 10 mm
[a] Data represent the mean SD of one experiment performed in tripli-
cate. [b] Single-dose inhibition data are from one experiment performed
in triplicate; confidence intervals, detailed single-dose inhibition data,
and full experimental details for the biological assays are given in the
Supporting Information.
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To understand the binding motif of the inhibitor scaffold, we
performed systematic synthetic modifications on 2. The intro-
duction of o-F substitution on the aromatic ring of the benzy-
lamino fragment resulted in a drastic loss of binding affinity,
whereas m-F and p-F substitutions were tolerated (SI Table S1).
This can be rationalized by the proposed binding motif and
the consequential negative interactions of the o-F substituent
with the backbone CO group of Phe220 (detailed SAR analysis
is given in the Supporting Information, Figure S3).
To improve the initial inhibitor scaffold 2 to a lead-like bind-
ing affinity and selectivity profile, water-mediated interactions
between the inhibitor and the target protein were targeted.[16a]
By introducing a carboxylic acid at the 4-position of the aro-
matic system on the left-hand side of the inhibitor scaffold to
address structural water HOH822 and a methoxy group at the
3-position of the aromatic system on the right-hand side of
the inhibitor scaffold to address water molecules HOH836 and
HOH915 (SI Figure S4), the potency could be improved sub-
stantially (3 : IC50=11 nm) while retaining the superb selectivity
profile (Table 1).
Furthermore, we elongated the methoxy group of inhibitor
3 with a propanoic acid fragment in order to verify the pro-
posed binding motif conclusively by merging the two binding
motifs of non-zinc-binding and zinc-binding MMP inhibitors.
This concept of combining those two motifs (S1’ non-zinc-
binding selectivity elements plus a zinc-binding group) has
been proposed in the past but has not yet been realized.[20] As
expected, inhibitor 4 indeed showed further improved binding
affinity (IC50=6 nm) and still retained an extraordinary selectivi-
ty profile (Table 1). Thus, to our knowledge, inhibitor 4 is the
first example of this type of combined binding motif.
Finally, an overlay of the X-ray crystal structure of the non-
zinc-binding MMP-13 inhibitor from PDB 2OW9 with the
docked inhibitor 4 supports the proposed binding motif and
suggests that the combination of allosteric and active site
binding elements is a widely applicable approach toward
highly potent and selective therapeutic agents (Figure 3).
In conclusion, we have demonstrated that structure-based
de novo design from scratch based on NPDFs is a powerful
technique for the efficient discovery of potent and selective
lead molecules for modulating therapeutically relevant targets.
In addition, by combining allosteric and active site binding
motifs, the presented approach delivered novel chemotypes of
zinc-binding as well as non-zinc-binding MMP-13 inhibitors.
This structured approach holds great promise for successful
application against other therapeutic targets as well. Finally,
our study validates the benefits of fragment-based techniques
in combination with natural products, which will reinforce the
significance of natural products for future drug-discovery ef-
forts.
Experimental Section
Compound 4 : Iodouracil derivative 5b (550 mg, 1.48 mmol,
1.0 equiv) and alkyne derivative 8g (405 mg, 1.55 mmol,
1.05 equiv) were dissolved in anhydrous DMF (8 mL) under N2 at-
mosphere. Pd(PPh3)4 (171 mg, 0.15 mmol, 0.1 equiv), CuI (56 mg,
0.30 mmol, 0.2 equiv) and Et3N (2 mL) were added at 20 8C. The re-
sulting mixture was stirred for 4 h at 20 8C. The reaction mixture
was quenched by adding H2O. The resulting suspension was acidi-
fied with 2m HCl. The precipitate was filtered off, washed with
H2O, suspended in MeOH and cooled to 20 8C. The precipitate
was filtered off and washed with cold MeOH. The crude product
was purified by reversed-phase flash chromatography and recrys-
tallization from MeOH/H2O (10:1). Yield: 295 mg, 0.58 mmol, 39%,
white solid; purity >99% (HPLC); dp: 224 8C; 1H NMR (700 MHz,
[D6]DMSO): d=12.55 (s, 2H), 11.84 (s, 1H), 9.16 (t, J=6.2 Hz, 1H),
8.46 (s, 1H), 7.93 (d, J=7.9 Hz, 2H), 7.44 (d, J=7.6 Hz, 2H), 7.25–
7.20 (m, 1H), 6.83–6.79 (m, 3H), 4.99 (s, 2H), 4.27 (d, J=6.2 Hz,
2H), 3.95 (t, J=6.2 Hz, 2H), 2.39 (t, J=7.8 Hz, 2H), 1.93 ppm (ps.
quin, J=6.8 Hz, 2H); 13C NMR (176 MHz, [D6]DMSO): d=174.06,
166.99, 161.60, 158.56, 152.21, 151.65, 149.90, 141.10, 140.30,
130.22, 129.70 (2C), 129.43, 127.59 (2C), 119.48, 113.59, 112.77,
95.64, 86.94, 77.52, 66.48, 50.92, 42.30, 30.16, 24.32 ppm; ESI-TOF-
HRMS: m/z 506.1549 [M+H]+ , calcd for C26H23N3O8: 505.1485,
found: 505.1475; Anal. calcd for C26H23N3O8 [%]: C 61.78, H 4.59, N
8.31, found [%]: C 61.55, H 4.54, N 8.24.
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